Effect of FTY720 on the Tissue Microenvironments of Acute Spinal Cord Injury

  • Xiaotian Li Dalian Third People's Hospital affiliated to Dalian Medical University
  • Linxuan Zou The First Affiliated Hospital of Dalian Medical University
  • Xin Han The Second Affiliated Hospital of Dalian Medical University & Naqu People's Hospital, Department of Orthopaedics
  • Zhuodong Fu The First Affiliated Hospital of Dalian Medical University
DOI: https://doi.org/10.18686/aem.v12i2.358
Keywords: FTY720, Neural Apoptosis, Acute Spinal Cord Injury

Abstract

Objectives: To observe the effect of FTY720 on the changes of tissue microenvironment after acute spinal cord injury (ASCI) in rats. Methods: A total of 168 female SD rats were randomly divided into A, B and C groups, with 56 rats in each group. In group A (Sham-operation group), only T9 laminectomy was performed without spinal cord injury, and 0.3 ml normal saline was given by gavage immediately after suture. Group B (control group) was given 0.3 ml normal saline by gavage, group C (treatment group) was given 0.3 ml FTY720 diluted in 3mg/kg normal saline by gavage. The rats were sacrificed at 6h, 12h, 24h, 72h, 7d and 21d after operation. The injured spinal cord (the corresponding part of group A) was taken for ultrathin section, and HE staining was used to observe the necrosis of the spinal cord, inflammatory cell infiltration, glial scar formation, and the size of the syringomyelia in each group. The ratio of syringomyelia area to spinal cord area was calculated 21 days after injury. SPSS 13.0 software was used for statistical analysis. Results: HE staining showed that the morphology of the spinal cord in group A was normal at each time point: At 12h to 48h after operation, progressive edema of the spinal cord and liquefaction necrosis of the injured central area were observed, accompanied by inflammatory cell infiltration, mainly neutrophils, lymphocytes and monocytes. At 12h and 72h after operation, the degree of inflammatory cell infiltration in group B was significantly higher than that in group C (P<0.05). The degree of lymphocyte infiltration in group C was significantly lower than that in group B 12 hours after operation (P< 0.05). At 72 hours after operation, the central area of the injury had formed an unorganized structure cavity, and a large number of inflammatory cells infiltrated around the cavity, mainly microglia/monocytes. The number of glial scar cells in group B was significantly higher than that in group C (P < 0.05). The syringomyelia formed 21 days after operation. The syringomyelia ratio in group B was significantly higher than that in group C (P<0.05). Conclusions: FTY720 can significantly improve neurological function in rats after ASCI possibly by inhibiting the inflammatory response after spinal cord injury, thereby reducing the secondary injury of the spinal cord.

References

[1] Cortez R, Levi AD. Acute spinal cord injury [J]. Critical Care Clinics, 1987, 3(2): 441-697.

[2] Tator CH, Fehlings MG. Review of the secondary injury theory of acute spinal cord trauma with emphasis on vascular mechanisms [J]. Journal of Neurosurgery, 1991, 75(1): 15-26.

[3] Tyor WR, Avgeropoulos N, Ohlandt G, et al. Treatment of spinal cord impact injury in the rat with transforming growth factor-beta [J]. Journal of the Neurological Sciences: Official Bulletin of the World Federation of Neurology, 2002, (1/2): 200.

[4] Merola A, et al. Attenuation of CNTF in ASCI treated with intravenous methylprednisolone [J]. The Spine Journal, 2002, 2(Supplement): 109.

[5] Bracken MB, Shepard MJ, Collins W, et al. Bracken M B, Shepard M J, Collins W F et alMethylprednisolone or naloxone treatment after acute spinal cord injury: I-year follow-up data. Results of the second National Acute Spinal Cord Injury Study, 1992. J Neurosurg 76: 23-31 [J]. Journal of Neurosurgery, 1992, 76(1): 23-31.

[6] Bracken M. A randomized, controlled trial of methylprednisolone or naloxone in the treatment of acute spinal cord injury [J]. N Engl J Med, 1990, 322.

[7] Beattie MS, Hermann GE, Rogers RC, et al. Cell death in models of spinal cord injury [J]. Progress in brain research, 2002: 137.

[8] John HR. Methylprednisolone for the Treatment of Acute Spinal Cord Injury: Point [J]. Neurosurgery, 2014, 61 Suppl 1(Suppl 1): 32.

[9] Bracken MB, Shepard MJ, Collins WF, et al. Methylprednisolone or naloxone treatment after acute spinal cord injury: I-year follow-up data [J]. Journal of Neurosurgery, 1992, 76(1): 23-31.

[10] Lambrechts D, Carmeliet P. VEGF at the neurovascular interface: therapeutic implications for motor neuron disease [J]. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2006, 1762(11–12): 1109-21.

[11] Ibarra A, Correa D, Willms K, et al. Effects of cyclosporin-A on immune response, tissue protection and motor function of rats subjected to spinal cord injury [J]. Brain Research, 2003, 979(1-2): 165-78.

[12] Fujita, Inoue, Yamamoto, et al. Fungal metabolites. Part 11. A potent immunosuppressive activity found in Isaria sinclairii metabolite [J]. The Journal of antibiotics, 1994.

[13] Kappos L, Antel J, Comi G, et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis [J]. N Engl J Med, 2006, 355(11): 1124-40.

[14] Budde K, Schmouder R L, Brunkhorst R, et al. Budde, K. et al. First human trial of FTY720, a novel immunomodulator, in stable renal transplant patients. J. Am. Soc. Nephrol. 13, 1073-1083 [J]. Journal of the American Society of Nephrology, 2002, 13(4): 1073-83.

[15] Zhang Z, Fauser U, Schluesener HJ. Early attenuation of lesional interleukin-16 up-regulation by dexamethasone and FTY720 in experimental traumatic brain injury [J]. Neuropathology and Applied Neurobiology, 2008.

[16] Zhang, Z, et al. FTY720 attenuates lesional interleukin-17+ cell accumulation in rat experimental autoimmune neuritis [J]. Neuropathology & Applied Neurobiology, 2009.

[17] Brinkmann, V. The Immune Modulator FTY720 Targets Sphingosine 1-Phosphate Receptors [J]. Journal of Biological Chemistry, 2002, 277(24): 21453-7.

[18] Schmouder R, Serra D, Wang Y, et al. FTY720: placebo-controlled study of the effect on cardiac rate and rhythm in healthy subjects [J]. Journal of Clinical Pharmacology, 2013, 46(8).

[19] Brinkmann V, Billich A, Baumruker T, et al. Erratum: Fingolimod (FTY720): Discovery and development of an oral drug to treat multiple sclerosis (Nature Reviews Drug Discovery (2010) 9 (883-897)) [J]. 2010.

[20] Li X K, Tamura A, Fujino M, et al. Induction of lymphocyte apoptosis in rat liver allograft with ongoing rejection by FTY720 [J]. Clinical & Experimental Immunology, 2010, 123(2): 331-9.

[21] López-Vales R, García-Alías G, Forés J, et al. FK506 reduces tissue damage and prevents functional deficit after spinal cord injury in the rat [J]. Journal of Neuroscience Research, 2010, 81(6): 827-36.

[22] Nagahara Y, Ikekita M, Shinomiya T. Immunosuppressant FTY720 induces apoptosis by direct induction of permeability transition and release of cytochrome c from mitochondria [J]. Journal of Immunology, 2000, 165(6): 3250-9.
Published
2023-06-01
Issue
Vol 12, No 2 (2023)
Section
Original Research Article

Copyright (c) 2023 Xiaotian Li

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Authors submitting to USP journals agree to publish their manuscript under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0) where authors agree to allow third parties to share their work (copy, distribute, transmit) and to adapt it, under the condition that the authors are given credit, and that in the event of reuse or distribution, the terms of this license are made clear

Authors retain copyright of their work, with first publication rights (online and print) granted to Universe Scientific Publishing or the owner of the journal in question.